Erratum to: Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria
© The Author(s). 2016
Published: 3 October 2016
The original article was published in BMC Musculoskeletal Disorders 2016 17:358
After publication of the original article , it came to the authors’ attention that in the third paragraph of the ‘Discussion’ section, the value of DAS28 in NEW included patients is indicated wrongly, although correctly cited in Table 2. The correct form of the erroneous sentence is as follows:
“NEW patients´ median disease activity according to the DAS28 before starting bDMARDs is in the lower range in BIOREG compared to other European bDMARD registries (4.46 compared to 4.2–6.6), while median HAQ-DI scores are in a comparable range (1.0 vs 0.8–1.9).”
To correct the original sentence, “(4.46 compared to 4.2–6.6)” should be updated to “(4.13 compared to 4.2–6.6)”, and “in the lower range” should replace “somewhat lower”.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Rintelen B, Zwerina J, Herold M, Singer F, Hitzelhammer J, Halder W, et al. Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria. BMC Musculoskelet Disord. 2016;17:358. doi:10.1186/s12891-016-1207-4.View ArticlePubMedPubMed CentralGoogle Scholar